Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - REGENERX BIOPHARMACEUTICALS INC | c03434exv99w1.htm |
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 14, 2010
REGENERX BIOPHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
| Delaware | 001-15070 | 52-1253406 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 15245 Shady Grove Road, Suite
470, Rockville, MD |
20850 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (301) 208-1991
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On July 14, 2010, RegeneRx Biopharmaceuticals, Inc. (the “Company”) will hold its annual meeting of stockholders at 11:00 am local time. J.J. Finkelstein, President and Chief Executive Officer of the Company, will present the slides attached to this report as Exhibit 99.1, which information is incorporated herein by reference.
The information in this Item 7.01, including the accompanying exhibit, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
|
99.1
|
Management Presentation, dated July 14, 2010. |
* * * * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENERX BIOPHARMACEUTICALS, INC.
Date: July 14, 2010
By: /s/ J.J. Finkelstein
Name: J.J.
Finkelstein
Title: President and Chief Executive Officer
EXHIBIT INDEX
| Exhibit No. | Description | |
|
99.1
|
Management Presentation, dated July 14, 2010. |